Intelligence · Clinical Development
Pipeline search results
Programs matching “control” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 67 pipeline programs matching "control" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
0.9% sodium chloride, GB-0895
Generate Biomedicines
severe uncontrolled asthma
1 trial -
0600-PG-PSC-218
Lacuna Pharma Pty Ltd
Allergic rhinoconjunctivitis with or without controlled asthma
1 trial -
2.16/VI/22
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
BaxHTN / D6970C00002
AstraZeneca AB
Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents, including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.
1 trial -
Baxdrostat
AstraZeneca
Uncontrolled Hypertension
2 trials -
CLI-05993AA5-06
Chiesi Farmaceutici S.p.A
Uncontrolled Asthma
1 trial -
Control
Hospital Authority, Hong Kong
Hallucinations, Verbal Auditory
1 trial -
D5180C00016
AstraZeneca AB
Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments
1 trial -
D5982C00006
AstraZeneca AB
Inadequately Controlled Asthma
1 trial -
D5982C00007
AstraZeneca AB
Severe and inadequately controlled asthma
1 trial -
D5982C00008
AstraZeneca AB
Severe and inadequately controlled asthma
1 trial -
Dupilumab Prefilled Syringe
Regeneron UK Limited
Asthma Control
1 trial -
Fasiglifam (TAK-875)
Takeda
Glycemic Control
1 trial -
Follitropin alfa
Ferring Pharmaceuticals
Controlled Ovarian Simulation
1 trial -
Grafalon 20 mg/ml concentrato per soluzione per infusione
The George Institute
To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.
1 trial -
H. pylori vaccine
Jiangsu Province Centers for Disease Control and Prevention
H. Pylori Infection
1 trial -
MLS-101-301
Mineralys Therapeutics
Uncontrolled and Resistant Hypertension
1 trial -
Magnesium Pantoprazole 20 mg
Takeda
Gastric pH Control
1 trial -
NN9535-4352
NovoThirteen
While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency
1 trial -
RM-493-035
Lacuna Pharma Pty Ltd
Improper function of certain messenger materials in the body that control body weight and hunger in people
1 trial -
Rivaroxaban (Xarelto, BAY59-7939)
Bayer HealthCare AG
Prevention & Control
1 trial -
S005201-175
The George Institute
Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin
1 trial -
Standard treatment: Control arm
United Therapeutics Europe Ltd
Cervical Carcinoma
1 trial -
rifapentine
Centers for Disease Control and Prevention
Tuberculosis
2 trials
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.